To explore drug treatment and pharmaceutical care of clinical pharmacists participating in abnormal liver function treatment of patient with cervical cancer and CHB (CHB) after chemotherapy.

A case of patient with cervical cancer and chronic hepatitis B after chemotherapy who hospitalized in Sichuan Cancer Hospital due to " cervical cancer Ⅱ_B, 24 days after two cycles of chemotherapy and planning to accept the third cycle of chemotherapy" in April 19, 2016 was selected as research subject. Clinical pharmacists in Sichuan Cancer Hospital participated in the development of the patient′s treatment protocol. The clinical data of this patient was collected by retrospective method. How the clinical pharmacists help clinicians developing effective treatment protocol through analysis of the causes of abnormal liver function, development of drug treatment protocol, pharmaceutical care with the use of evidence-based medical thinking were analyzed and summarized.

①History-taking results were as follows. This patient had a history of CHB and had not received any treatment. Before the first and second cycle of chemotherapy in Sichuan Cancer Hospital, her liver functions were normal. The hepatitis B surface antigen (HBsAg), hepatitis B virus e antibody (HBeAb) and hepatitis B virus core antibody (HBcAb) all were positive before receiving the third cycle of chemotherapy, and the liver function examination indicated that the patients had severe liver function injury. ②The clinical pharmacists considered the abnormal liver function was caused by reactivation of hepatitis B virus (HBV) after chemotherapy, and suggested that the clinicians should suspend chemotherapy and use reduced glutathione, anti-inflammatory magnesium isoglycyrrhizinate and bicyclol tablets which could reduce the levels of alanine transaminase (ALT) and aspartate aminotransferase (ALT) to protect the patient′s liver functions, then change to anti-inflammatory drugs and essential phospholipids after liver functions being stable or normal. At the same time, the clinical pharmacists suggested that the clinicians should examine the patient′s HBV DNA and give nucleoside antivirus treatment according to the HBV DNA load. The clinicians adopted the recommendations of clinical pharmacists. After receiving the positive treatments, the liver functions of the patient was recovered, as the chemotherapy contraindication was eliminated, the third cycle of chemotherapy was successfully completed and the chemotherapy treatment was the same as the first and second cycles of chemotherapy.

For patients with cervical cancer and CHB undergoing chemotherapy, the liver functions and HBV monitoring should be emphasized, and the liver-protective and anti-HBV drugs should be used properly. The clinical pharmacists should analyze the risks of related medicinal treatments and assist clinicians to develop optimal chemotherapy protocol according to the patient′s condition and the characteristics of chemotherapy drugs.